Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne, Carterra Partner on COVID-19 Variant Analysis

NEW YORK ─ Bio-Techne and Carterra said Wednesday that they are collaborating to study more than 40 COVID-19 variants, including the Delta variant and other emerging variants as they are discovered.

Financial and other terms of the collaboration were not disclosed.

Minneapolis-based Bio-Techne has developed SARS-CoV-2 variants to fast-track the development of a scalable assay to measure the risk that new variants may evade the immune system, the firms said.

The collaborators are using a high-throughput analytical platform, LSA, developed by Salt Lake City-based Carterra, to characterize panels of SARS-CoV-2 spike and receptor-binding domain variants in an assay.

LSA combines flow printing microfluidics with high-throughput surface plasmon resonance to enable screening and characterization of antibody or variant libraries, including full kinetic profiles. The platform generates binding data for 384 proteins on one chip and can assay up to 1,152 patient samples in a single unattended run, the firms said.

Using 2 µL of patient serum, Carterra LSA generates insights with more than 120 data points, including a variant profile, ACE-2 blocking potential, and isotyping profiles of immunoglobin response, the firms added.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.